The statements that Mullholland makes at the beginning of the CCs states pretty much what the risks are so being properly informed I believe is achieved thru that process. Shareholders just don’t listen to that part because it’s not the “ meat” of the meeting..A CEO saying their stock is under valued is nothing new. Every CEO I have met says their stock is undervalued but most don’t say it in conference calls, unless they are Elon Musk. NP gets off track when he veers off of the script and I think it’s time for Dr. Kelly as chairman of the board to pull NP back, NP kick off the CCs and then turn it over to the experts in the company to talk about the subject matter. I have been a big critic of NPs musings because , as a retired exec I have been in more quarterly analyst meetings than I can count and his off the cuff comments are problematic . If we were on a respected exchange the meetings would cause downgrades by analysts ....but as far as lawsuits against Cytodyn for what is said in the meetings , the lawsuits don’t hold water